Antiangiogenic therapies for non-small-cell lung cancer

Suresh S. Ramalingam; Chandra P. Belani

doi:10.2217/EBO.11.217

Antiangiogenic therapies for non-small-cell lung cancer

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Angiogenesis is critical for tumor growth and metastasis. VEGF is an important mediator of angiogenesis and has emerged as a leading target for cancer therapy. Bevacizumab, a monoclonal antibody to VEGF, has demonstrated improved overall survival when given in combination with carboplatin and paclitaxel in advanced nonsquamous non-small-cell lung cancer. VEGF receptor tyrosine kinase inhibitors are active as monotherapy in advanced non-smallcell lung cancer but have not improved survival when given in combination with chemotherapy. Identification of predictive biomarkers for antiangiogenic agents is a major focus of ongoing investigations. Agents targeting important mediators of angiogenesis are currently being evaluated.

Original language	English (US)
Title of host publication	Advances in Personalized Therapy for Lung Cancer
Publisher	Future Medicine Ltd.
Pages	39-51
Number of pages	13
ISBN (Electronic)	9781780840345
ISBN (Print)	9781780841175
DOIs	https://doi.org/10.2217/EBO.11.217
State	Published - Nov 1 2011

All Science Journal Classification (ASJC) codes

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/EBO.11.217

Cite this

@inbook{a34c1b15706f4187ba6f6f035c63f347,

title = "Antiangiogenic therapies for non-small-cell lung cancer",

abstract = "Angiogenesis is critical for tumor growth and metastasis. VEGF is an important mediator of angiogenesis and has emerged as a leading target for cancer therapy. Bevacizumab, a monoclonal antibody to VEGF, has demonstrated improved overall survival when given in combination with carboplatin and paclitaxel in advanced nonsquamous non-small-cell lung cancer. VEGF receptor tyrosine kinase inhibitors are active as monotherapy in advanced non-smallcell lung cancer but have not improved survival when given in combination with chemotherapy. Identification of predictive biomarkers for antiangiogenic agents is a major focus of ongoing investigations. Agents targeting important mediators of angiogenesis are currently being evaluated.",

author = "Ramalingam, {Suresh S.} and Belani, {Chandra P.}",

year = "2011",

month = nov,

day = "1",

doi = "10.2217/EBO.11.217",

language = "English (US)",

isbn = "9781780841175",

pages = "39--51",

booktitle = "Advances in Personalized Therapy for Lung Cancer",

publisher = "Future Medicine Ltd.",

address = "United Kingdom",

}

TY - CHAP

T1 - Antiangiogenic therapies for non-small-cell lung cancer

AU - Ramalingam, Suresh S.

AU - Belani, Chandra P.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Angiogenesis is critical for tumor growth and metastasis. VEGF is an important mediator of angiogenesis and has emerged as a leading target for cancer therapy. Bevacizumab, a monoclonal antibody to VEGF, has demonstrated improved overall survival when given in combination with carboplatin and paclitaxel in advanced nonsquamous non-small-cell lung cancer. VEGF receptor tyrosine kinase inhibitors are active as monotherapy in advanced non-smallcell lung cancer but have not improved survival when given in combination with chemotherapy. Identification of predictive biomarkers for antiangiogenic agents is a major focus of ongoing investigations. Agents targeting important mediators of angiogenesis are currently being evaluated.

AB - Angiogenesis is critical for tumor growth and metastasis. VEGF is an important mediator of angiogenesis and has emerged as a leading target for cancer therapy. Bevacizumab, a monoclonal antibody to VEGF, has demonstrated improved overall survival when given in combination with carboplatin and paclitaxel in advanced nonsquamous non-small-cell lung cancer. VEGF receptor tyrosine kinase inhibitors are active as monotherapy in advanced non-smallcell lung cancer but have not improved survival when given in combination with chemotherapy. Identification of predictive biomarkers for antiangiogenic agents is a major focus of ongoing investigations. Agents targeting important mediators of angiogenesis are currently being evaluated.

UR - http://www.scopus.com/inward/record.url?scp=84956715465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956715465&partnerID=8YFLogxK

U2 - 10.2217/EBO.11.217

DO - 10.2217/EBO.11.217

M3 - Chapter

AN - SCOPUS:84956715465

SN - 9781780841175

SP - 39

EP - 51

BT - Advances in Personalized Therapy for Lung Cancer

PB - Future Medicine Ltd.

ER -

Antiangiogenic therapies for non-small-cell lung cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this